Piperacillin/tazobactumAlternative Names: YH-1177; YH-1177D
Latest Information Update: 28 Jul 2016
At a glance
- Originator Yuhan
- Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors; Glucocorticoid receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Otitis media
Most Recent Events
- 01 Jul 2016 Yuhan Corporation plans a phase I/II trial for Otitis media in South Korea (NCT02817347)
- 01 Jun 2016 Phase-I/II clinical trials in Otitis media in South Korea (Otic)
- 15 Dec 2014 Preclinical trials in Otitis media in South Korea (Otic)